Astellas Signed an Exclusive License and Development Agreement with Selecta Biosciences for Xork IgG Protease
Shots:
- Selecta to receive $10M up front, ~$340M in additional development and commercial milestones along with royalties on commercial sales. Xork used as a pre-treatment for AT845
- Selecta will lead the development & manufacturing of Xork and will have the rights for the development of additional indications beyond Pompe disease. Astellas get an exclusive commercialization right for Pompe disease & can combine Xork with an Astellas gene therapy product AT845
- The agreement enables Astellas to advance its gene therapy portfolio & also helps to deliver transformative gene therapy treatments to LOPD patients who may not be eligible for clinical trials or treatment with Astellas' AT845
Ref: PRNewswire | Image: Astellas
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
